Literature DB >> 14720137

Immunohistochemical analysis of centromere protein F expression in buccal and gingival squamous cell carcinoma.

Renelson L Esguerra1, Lin Jia, Tomoatsu Kaneko, Kei Sakamoto, Norihiko Okada, Minoru Takagi.   

Abstract

Centromere protein F (CENP-F) expression (localization and characteristics) in relation to tumor clinicopathological parameters was immunohistochemically examined and evaluated in 47 archival biopsy specimens of buccal and gingival squamous cell carcinomas (SCC). Centromere protein F expression was detected in 79% of the samples. An increase in the labeling index (LI) with WHO grading was obtained (P < 0.05). Correlations were obtained between the CENP-F LI and tumor size (P < 0.05). Immunoelectron microscopy showed CENP-F nuclear staining as punctate or fine dots. The present study shows that CENP-F expression and detection of a more specific cell subpopulation presents a theoretical advantage for the analysis of the precise cell cycle of G2 to M cells, compared to Ki-67.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720137     DOI: 10.1111/j.1440-1827.2004.01596.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  3 in total

1.  Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study.

Authors:  Zhen-Yan Hu; Li-Juan Pang; Yan Qi; Xue-Ling Kang; Jian-Ming Hu; Lianghai Wang; Kun-Peng Liu; Yuan Ren; Mei Cui; Li-Li Song; Hong-An Li; Hong Zou; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation.

Authors:  Fiona Moghaddas; Fredrick Joshua; Roberta Taylor; Marvin J Fritzler; Ban Hock Toh
Journal:  BMC Res Notes       Date:  2016-02-11

3.  Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay.

Authors:  Simon Welner; Nicole Hartwig Trier; Morten Frisch; Henning Locht; Paul Robert Hansen; Gunnar Houen
Journal:  Mol Cancer       Date:  2013-08-26       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.